--- title: "Editas Medicine (EDIT) stock: news and investor profile" url: "https://aibio.space/companies/editas-medicine/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Editas Medicine, Inc. (NASDAQ: EDIT), United States. The directory classifies it as Biotechnology." --- EDIT Editas Medicine, Inc. NASDAQ · United States # Editas Medicine (EDIT) news Listings · 2025-06-02 ## [Editas Medicine holders approve doubling authorized common stock to 390,000,000](https://aibio.space/news/editas-medicine-holders-approve-doubling-authorized-common-stock-390/) The amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision. ## Latest Editas Medicine news 1. 2024-12-12 Distress [Editas Medicine ends reni-cel program, cuts about 180 positions (65% of workforce)](https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/) The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027. ## Editas Medicine at a glance - **Ticker**: EDIT - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $211.6 million ### Related companies - [Cognition Therapeutics](https://aibio.space/companies/cognition-therapeutics/) NASDAQ: CGTX - [Microbot Medical](https://aibio.space/companies/microbot-medical/) NASDAQ: MBOT - [Faeth Therapeutics](https://aibio.space/companies/faeth-therapeutics/) NASDAQ: FTH - [Korsana Biosciences](https://aibio.space/companies/korsana-biosciences/) NASDAQ: KRSA - [Mineralys Therapeutics](https://aibio.space/companies/mineralys-therapeutics/) NASDAQ: MLYS - [DiaMedica Therapeutics](https://aibio.space/companies/diamedica-therapeutics/) NASDAQ: DMAC - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [Kura Oncology](https://aibio.space/companies/kura-oncology/) NASDAQ: KURA ### Also on NASDAQ - [Lucid Diagnostics](https://aibio.space/companies/lucid-diagnostics/) LUCD - [ORTHOPEDIATRICS CORP](https://aibio.space/companies/orthopediatrics/) KIDS - [Psyence Biomedical](https://aibio.space/companies/psyence-biomedical/) PBM - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) ACRS - [Pluri](https://aibio.space/companies/pluri/) PLUR - [Kamada](https://aibio.space/companies/kamada/) KMDA ## Editas Medicine annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$90.0 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | [$199.2 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | | Net income (loss) | [-$160.1 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | [-$237.1 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | | Cash from operations | [-$165.2 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | [-$210.3 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | | Cash and equivalents | [$146.6 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000083/) | [$131.5 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | | Short-term investments | [$0](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000083/) | [$138.4 million](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000017/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $181.8 million, plus short-term investments of $29.8 million, $211.6 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Editas Medicine What is the ticker symbol of Editas Medicine? Editas Medicine, Inc. trades under the ticker EDIT on NASDAQ. Where is Editas Medicine listed? Editas Medicine, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:8EM; LS:A2AC4K; LSE:0IFK; LSX:A2AC4K. What is the SEC CIK of Editas Medicine? The SEC Central Index Key (CIK) for Editas Medicine, Inc. is 1650664. Its filings are on SEC EDGAR. How many shares does Editas Medicine have outstanding? 153,580,035 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Editas Medicine listed under? Our directory records Editas Medicine, Inc. under United States. What does Editas Medicine do? Our directory classifies Editas Medicine, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Editas Medicine? The ISIN recorded for Editas Medicine, Inc. is US28106W1036. Does aibio.space cover Editas Medicine? aibio.space lists Editas Medicine, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Editas Medicine incorporated? SEC records list its state or country of incorporation as DE. Is Editas Medicine profitable? Editas Medicine, Inc. reported a net loss of $160.1 million for the fiscal year ended Dec 31, 2025, and used $165.2 million of cash in operations, per its annual report to the SEC. How much does Editas Medicine spend on research and development? $90.0 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Editas Medicine have? $211.6 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Editas Medicine (EDIT) stock news? Our latest story on Editas Medicine, dated Jun 2, 2025: "Editas Medicine holders approve doubling authorized common stock to 390,000,000". The amended charter also lifts total authorized capital stock to 395,000,000 shares. Holders also approved a revised 2015 Stock Incentive Plan that removes its evergreen provision. [Source](https://aibio.space/news/editas-medicine-holders-approve-doubling-authorized-common-stock-390/). How long will Editas Medicine's cash last? From our story of Dec 12, 2024: The company says it is acting to extend its cash runway and refocus resources on in vivo pipeline development. [Source](https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/). Is Editas Medicine in financial distress? Our latest distress story, dated Dec 12, 2024: "Editas Medicine ends reni-cel program, cuts about 180 positions (65% of workforce)". The company expects costs of $55.0 million to $70.0 million for the discontinuation and $14.0 million to $18.0 million for the workforce reduction. It now sees cash lasting into the second quarter of 2027. [Source](https://aibio.space/news/editas-medicine-ends-reni-cel-program-cuts-about-180-positions-65/). ## Investor discussion: Editas Medicine Members talk about Editas Medicine (EDIT). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Editas Medicine, newest first. Each line links the filing it comes from. 1. 2026-04-07 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000030/edit-20260401.htm) 2. 2025-06-02 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1650664/000165066425000086/edit-20250529.htm) 3. 2024-12-12 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,5.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1650664/000165066424000141/edit-20241211.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:EDIT on TradingView](https://www.tradingview.com/symbols/NASDAQ-EDIT/). ## SEC filings and registration - **SEC name**: Editas Medicine, Inc. - **CIK**: 1650664 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: EDIT (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 11 HURLEY ST., CAMBRIDGE, MA, 02141 - **Phone**: 617-401-9000 - **Shares outstanding**: 153,580,035 as of 2026-07-31 (10-Q filed 2026-08-05) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000093/edit-20261008.htm) filed 2026-10-08 - [S-3](https://www.sec.gov/Archives/edgar/data/1650664/000110465926103906/tm2624301-1_s3.htm) filed 2026-08-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000083/edit-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000082/edit-20260803.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1650664/000165066426000063/edit-20260617.htm) filed 2026-06-18 - [424B5](https://www.sec.gov/Archives/edgar/data/1650664/000110465926066382/tm2615433-4_424b5.htm) filed 2026-05-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1650664/000110465926066317/tm2615565d3_8k.htm) filed 2026-05-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1650664/000110465926066021/tm2615565d2_8k.htm) filed 2026-05-26 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001650664), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Editas Medicine, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker EDIT, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Editas Medicine, Inc. - **Ticker**: EDIT - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US28106W1036 - **Other listed symbols**: GETTEX:8EM; LS:A2AC4K; LSE:0IFK; LSX:A2AC4K - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-EDIT/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/editas-medicine/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Editas Medicine (EDIT) stock: news and investor profile", 2026-10-31, https://aibio.space/companies/editas-medicine/